Search

Your search keyword '"Vellone M. (ORCID:0000-0002-7628-4092)"' showing total 10 results
Start Over Author "Vellone M. (ORCID:0000-0002-7628-4092)"
10 results on '"Vellone M. (ORCID:0000-0002-7628-4092)"'

1. Survival by Number and Sites of Resections of Recurrence after First Curative Resection of Colorectal Liver Metastases

Author

Panettieri, Elena, Kim, B. J., Kawaguchi, Y., Ardito, Francesco, Mele, C., De Rose, Agostino Maria, Vellone, Maria, Chun, Y. S., Tzeng, C. W. D., Aloia, T. A., Giuliante, Felice, Vauthey, J. N., Panettieri E., Ardito F. (ORCID:0000-0003-1596-2862), De Rose A. M., Vellone M. (ORCID:0000-0002-7628-4092), Giuliante F. (ORCID:0000-0001-9517-8220), Panettieri, Elena, Kim, B. J., Kawaguchi, Y., Ardito, Francesco, Mele, C., De Rose, Agostino Maria, Vellone, Maria, Chun, Y. S., Tzeng, C. W. D., Aloia, T. A., Giuliante, Felice, Vauthey, J. N., Panettieri E., Ardito F. (ORCID:0000-0003-1596-2862), De Rose A. M., Vellone M. (ORCID:0000-0002-7628-4092), and Giuliante F. (ORCID:0000-0001-9517-8220)

Abstract

Background Recurrence after curative hepatectomy for colorectal liver metastases (CRLM) is common. We sought to determine if number and sites of resections of recurrence after hepatectomy for CRLM impact survival. Methods The study included patients who underwent resection of recurrence following complete curative-intent resection of CRLM during 1998-2016 at two academic medical centers in Houston, USA, and Rome, Italy. The survival impacts of number and sites of resections of recurrence were evaluated. Patients with synchronous extrahepatic disease at curative CRLM resection were excluded. Results Among 2163 patients who underwent curative hepatectomy, 1456 (67.3%) developed a recurrence. Four hundred seventy-eight patients underwent one (322/478; 67.4%) or two or more (156/478; 32.6%) resections of recurrence. The 5-year overall survival (OS) rate was higher in patients with resected than unresected recurrence (70.2% vs. 24.0%; p < 0.001). In patients who underwent only one resection of recurrence, the 5-year OS rate differed by location (lung, 81.6%; liver, 64.3%; other, 54.1%). In patients who underwent two or more resections of recurrence, the 5-year OS rate was similar for liver-only resection (87.5%) and resection of liver and other sites (66.1%) (p = 0.223) and for liver-only resection and other-sites-only resection (80.7%) (p = 0.258); 5-year OS rate by site of first resection of recurrence did not differ between liver (78.5%) and lung (81.8%) (p = 0.502) but was worse for other sites (61.1%) than for lung (p = 0.045). Conclusion When recurrence after initial CRLM resection is resectable, the ability to undergo resection was associated with improved survival and can be considered as an option regardless of the number of recurrence and resection. Sites of resection of recurrence impact survival and should be considered.

Published
2022

2. The Impact of KRAS Mutational Status on Long-Term Survival following Liver Resection for Hilar Cholangiocarcinoma

Author

Ardito, Francesco, Razionale, Francesco, Campisi, Andrea, Carlino, Angela, Vellone, Maria, Vani, S., Larocca, Luigi Maria, Giuliante, Felice, Ardito F. (ORCID:0000-0003-1596-2862), Razionale F., Campisi A., Carlino A., Vellone M. (ORCID:0000-0002-7628-4092), Larocca L. M. (ORCID:0000-0003-1739-4758), Giuliante F. (ORCID:0000-0001-9517-8220), Ardito, Francesco, Razionale, Francesco, Campisi, Andrea, Carlino, Angela, Vellone, Maria, Vani, S., Larocca, Luigi Maria, Giuliante, Felice, Ardito F. (ORCID:0000-0003-1596-2862), Razionale F., Campisi A., Carlino A., Vellone M. (ORCID:0000-0002-7628-4092), Larocca L. M. (ORCID:0000-0003-1739-4758), and Giuliante F. (ORCID:0000-0001-9517-8220)

Abstract

KRAS mutation is reportedly associated with poor prognosis in patients with different cancer types. However, mutational data on hilar cholangiocarcinoma are few and controversial. The aim of this study was to evaluate the rate of KRAS mutations in a single-center homogeneous population resected for hilar cholangiocarcinoma and the subsequent impact on prognosis. KRAS mutation status was evaluated in 54 patients undergoing major hepatectomy combined with resection of the main biliary confluence and regional lymphadenectomy for hilar cholangiocarcinoma between 2001 and 2019. Among these 54 patients, 12 (22.2%) had a KRAS mutation. KRAS mutation was not related with pathologic characteristics of the tumor. Five-year overall survival (OS) in patients with KRAS mutation was significantly lower than that observed in patients with KRAS wild type (0 vs. 49.2%, respectively; p = 0.003). In the multivariable analysis; independent predictors of poor OS were KRAS mutation (HR = 5.384; p = 0.003) and lymph node metastases (HR = 2.805; p = 0.023). The results of our study suggested that KRAS mutation in hilar cholangiocarcinoma was not rarely observed. KRAS mutation was an independent strong predictor of poor OS. KRAS mutation analysis should be included in the routine pathologic evaluation of resected hilar cholangiocarcinoma in order to better stratify prognosis

Published
2022

3. Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report

Author

Calegari, M. A., Stefano, B. D., Basso, M., Carbone, C., Camarda, F., Ribelli, M., Anghelone, A., Vivolo, R., Bensi, M., Martini, M., Pozzo, C., Vellone, M., Ardito, F., Salvatore, L., Giuliante, F., Tortora, G., Calegari M. A., Basso M., Camarda F., Anghelone A., Vivolo R., Bensi M., Martini M. (ORCID:0000-0002-6260-6310), Pozzo C., Vellone M. (ORCID:0000-0002-7628-4092), Ardito F. (ORCID:0000-0003-1596-2862), Salvatore L., Giuliante F. (ORCID:0000-0001-9517-8220), Tortora G. (ORCID:0000-0002-1378-4962), Calegari, M. A., Stefano, B. D., Basso, M., Carbone, C., Camarda, F., Ribelli, M., Anghelone, A., Vivolo, R., Bensi, M., Martini, M., Pozzo, C., Vellone, M., Ardito, F., Salvatore, L., Giuliante, F., Tortora, G., Calegari M. A., Basso M., Camarda F., Anghelone A., Vivolo R., Bensi M., Martini M. (ORCID:0000-0002-6260-6310), Pozzo C., Vellone M. (ORCID:0000-0002-7628-4092), Ardito F. (ORCID:0000-0003-1596-2862), Salvatore L., Giuliante F. (ORCID:0000-0001-9517-8220), and Tortora G. (ORCID:0000-0002-1378-4962)

Abstract

• Standard chemotherapy plus surgery yields to unsatisfying results in BRAF-mutated colorectal liver metastases (CLM). Combination of targeted agents (encorafenib, a BRAF inhibitor, and cetuximab, an anti-EGFR) is the new standard of care for BRAF V600E-mutated mCRC refractory to a first-line standard chemotherapy. Up to now no evidence is available concerning the activity of this novel treatment as conversion therapy in CLM setting. • Our case provides evidence, for the first time to our knowledge, of the activity of encorafenib plus cetuximab as conversion regimen for BRAF V600E-mutated CLM. Additional observations in this case report concern mechanisms underlying rapid occurrence of acquired resistance and the role of CEA serum levels as biomarker to monitor treatment activity and occurrence of resistance, allowing to optimize the timing of surgery. • Further evidence on the role of doublet targeted regimen (encorafenib plus cetuximab) as conversion treatment in the setting of BRAF-mutant CLM is warranted.

Published
2021

4. Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis

Author

Orlandi, Armando, Pontolillo, Letizia, Mele, Caterina, Pasqualoni, Mariangela, Pannunzio, Sergio, Cannizzaro, Maria Chiara, Cutigni, Claudia, Palazzo, A., Garufi, Giovanna, Vellone, Maria, Ardito, Francesco, Franceschini, Gianluca, Sanchez, A. M., Cassano, Alessandra, Giuliante, Felice, Bria, Emilio, Tortora, Giampaolo, Orlandi A. (ORCID:0000-0001-5253-4678), Pontolillo L., Mele C., Pasqualoni M., Pannunzio S., Cannizzaro M. C., Cutigni C., Garufi G., Vellone M. (ORCID:0000-0002-7628-4092), Ardito F. (ORCID:0000-0003-1596-2862), Franceschini G. (ORCID:0000-0002-2950-3395), Cassano A. (ORCID:0000-0002-3311-7163), Giuliante F. (ORCID:0000-0001-9517-8220), Bria E. (ORCID:0000-0002-2333-704X), Tortora G. (ORCID:0000-0002-1378-4962), Orlandi, Armando, Pontolillo, Letizia, Mele, Caterina, Pasqualoni, Mariangela, Pannunzio, Sergio, Cannizzaro, Maria Chiara, Cutigni, Claudia, Palazzo, A., Garufi, Giovanna, Vellone, Maria, Ardito, Francesco, Franceschini, Gianluca, Sanchez, A. M., Cassano, Alessandra, Giuliante, Felice, Bria, Emilio, Tortora, Giampaolo, Orlandi A. (ORCID:0000-0001-5253-4678), Pontolillo L., Mele C., Pasqualoni M., Pannunzio S., Cannizzaro M. C., Cutigni C., Garufi G., Vellone M. (ORCID:0000-0002-7628-4092), Ardito F. (ORCID:0000-0003-1596-2862), Franceschini G. (ORCID:0000-0002-2950-3395), Cassano A. (ORCID:0000-0002-3311-7163), Giuliante F. (ORCID:0000-0001-9517-8220), Bria E. (ORCID:0000-0002-2333-704X), and Tortora G. (ORCID:0000-0002-1378-4962)

Abstract

The liver represents the first metastatic site in 5–12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC patients who had undergone an LM after a multidisciplinary Tumor Board discussion at the Hepatobiliary Surgery Unit of Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS in Rome, between January 1994 and December 2019 was conducted. The primary endpoint was overall survival (OS) after a MBC-LM; the secondary endpoint was the disease-free interval (DFI) after surgery. Forty-nine MBC patients underwent LM, but clinical data were only available for 22 patients. After a median follow-up of 71 months, median OS and DFI were 67 months (95% CI 45–103) and 15 months (95% CI 11–46), respectively. At univariate analysis, the presence of a negative resection margin (R0) was the only factor that statistically significantly influenced OS (78 months versus 16 months; HR 0.083, p < 0.0001) and DFI (16 months versus 5 months; HR 0.17, p = 0.0058). A LM for MBC might represent a therapeutic option for selected patients. The radical nature of the surgical procedure performed in a high-flow center and after a multidisciplinary discussion appears essential for this therapeutic option.

Published
2021

5. Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis

Author

Orlandi, Armando, Pontolillo, Letizia, Mele, Caterina, Pasqualoni, Mariangela, Pannunzio, Sergio, Cannizzaro, Maria Chiara, Cutigni, Claudia, Palazzo, A., Garufi, Giovanna, Vellone, Maria, Ardito, Francesco, Franceschini, Gianluca, Sanchez, A. M., Cassano, Alessandra, Giuliante, Felice, Bria, Emilio, Tortora, Giampaolo, Orlandi A. (ORCID:0000-0001-5253-4678), Pontolillo L., Mele C., Pasqualoni M., Pannunzio S., Cannizzaro M. C., Cutigni C., Garufi G., Vellone M. (ORCID:0000-0002-7628-4092), Ardito F. (ORCID:0000-0003-1596-2862), Franceschini G. (ORCID:0000-0002-2950-3395), Cassano A. (ORCID:0000-0002-3311-7163), Giuliante F. (ORCID:0000-0001-9517-8220), Bria E. (ORCID:0000-0002-2333-704X), Tortora G. (ORCID:0000-0002-1378-4962), Orlandi, Armando, Pontolillo, Letizia, Mele, Caterina, Pasqualoni, Mariangela, Pannunzio, Sergio, Cannizzaro, Maria Chiara, Cutigni, Claudia, Palazzo, A., Garufi, Giovanna, Vellone, Maria, Ardito, Francesco, Franceschini, Gianluca, Sanchez, A. M., Cassano, Alessandra, Giuliante, Felice, Bria, Emilio, Tortora, Giampaolo, Orlandi A. (ORCID:0000-0001-5253-4678), Pontolillo L., Mele C., Pasqualoni M., Pannunzio S., Cannizzaro M. C., Cutigni C., Garufi G., Vellone M. (ORCID:0000-0002-7628-4092), Ardito F. (ORCID:0000-0003-1596-2862), Franceschini G. (ORCID:0000-0002-2950-3395), Cassano A. (ORCID:0000-0002-3311-7163), Giuliante F. (ORCID:0000-0001-9517-8220), Bria E. (ORCID:0000-0002-2333-704X), and Tortora G. (ORCID:0000-0002-1378-4962)

Abstract

The liver represents the first metastatic site in 5–12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC patients who had undergone an LM after a multidisciplinary Tumor Board discussion at the Hepatobiliary Surgery Unit of Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS in Rome, between January 1994 and December 2019 was conducted. The primary endpoint was overall survival (OS) after a MBC-LM; the secondary endpoint was the disease-free interval (DFI) after surgery. Forty-nine MBC patients underwent LM, but clinical data were only available for 22 patients. After a median follow-up of 71 months, median OS and DFI were 67 months (95% CI 45–103) and 15 months (95% CI 11–46), respectively. At univariate analysis, the presence of a negative resection margin (R0) was the only factor that statistically significantly influenced OS (78 months versus 16 months; HR 0.083, p < 0.0001) and DFI (16 months versus 5 months; HR 0.17, p = 0.0058). A LM for MBC might represent a therapeutic option for selected patients. The radical nature of the surgical procedure performed in a high-flow center and after a multidisciplinary discussion appears essential for this therapeutic option.

Published
2021

6. Laparoscopic left hepatectomy for primary intrahepatic lithiasis: surgical technique

Author

Ardito, Francesco, Mele, C., Vellone, Maria, Giuliante, Felice, Ardito F. (ORCID:0000-0003-1596-2862), Vellone M. (ORCID:0000-0002-7628-4092), Giuliante F. (ORCID:0000-0001-9517-8220), Ardito, Francesco, Mele, C., Vellone, Maria, Giuliante, Felice, Ardito F. (ORCID:0000-0003-1596-2862), Vellone M. (ORCID:0000-0002-7628-4092), and Giuliante F. (ORCID:0000-0001-9517-8220)

Abstract

Primary intrahepatic lithiasis (PIHL) is defined by the presence of stones that generates in the liver at the level of cystic dilatations of the intrahepatic biliary tree. When PIHL is unilateral and limited to a single hemiliver or segment, liver resection may be considered the treatment of choice, because it removes the stones together with the atrophic parenchyma with anomalous bile duct dilations and strictures, that are associated with the risk of developing cholangiocarcinoma. PIHL can represent a valid indication for the minimally invasive approach. Localized PIHL is particularly prevalent in the left lateral segment. Left hepatectomy by minimally invasive approach may be considered as a standardized procedure and an excellent choice to treat the disease, resulting in better operative results than that reported after open procedure.

Published
2020

7. The impact of personalized nutritional support on postoperative outcome within the enhanced recovery after surgery (ERAS) program for liver resections: results from the NutriCatt protocol

Author

Ardito, Francesco, Lai, Q., Rinninella, Emanuele, Mimmo, A., Vellone, Maria, Panettieri, Elena, Adducci, Enrica, Cintoni, M., Mele, Maria Cristina, Gasbarrini, Antonio, Giuliante, Felice, Ardito F. (ORCID:0000-0003-1596-2862), Rinninella E. (ORCID:0000-0002-9165-2367), Vellone M. (ORCID:0000-0002-7628-4092), Panettieri E., Adducci E. (ORCID:0000-0002-8977-762X), Mele M. C. (ORCID:0000-0003-0153-5819), Gasbarrini A. (ORCID:0000-0002-7278-4823), Giuliante F. (ORCID:0000-0001-9517-8220), Ardito, Francesco, Lai, Q., Rinninella, Emanuele, Mimmo, A., Vellone, Maria, Panettieri, Elena, Adducci, Enrica, Cintoni, M., Mele, Maria Cristina, Gasbarrini, Antonio, Giuliante, Felice, Ardito F. (ORCID:0000-0003-1596-2862), Rinninella E. (ORCID:0000-0002-9165-2367), Vellone M. (ORCID:0000-0002-7628-4092), Panettieri E., Adducci E. (ORCID:0000-0002-8977-762X), Mele M. C. (ORCID:0000-0003-0153-5819), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Giuliante F. (ORCID:0000-0001-9517-8220)

Abstract

Background: Malnutrition in liver surgery is correlated with higher postoperative complications and longer length of hospital stay (LOHS), the same items that ERAS programs try to optimize. However, to date, standardized dietary protocols have not been defined within ERAS programs. Aim of this study was to evaluate the impact on LOHS and postoperative complications, of a personalized nutritional protocol (NutriCatt) with diet and oral branched-chain amino acid (BCAA) supplementation, adopted within the ERAS program. Methods: 1960 consecutive liver resections were performed from January 2000 to September 2018. Exclusion criteria: perihilar cholangiocarcinoma, simultaneous colorectal and liver resections. Four groups for analysis: resections before 2009 (1st period); from 2009 to 2016 (2nd period, including laparoscopic resections); between 2016 and September 2017 (ERAS); after September 2017 (ERAS + NutriCatt). Results: LOHS declined (p < 0.0001), from a median of 10 days (1st period) to 8, 7 and 6 in 2nd period, ERAS and ERAS + NutriCatt groups, respectively. At multivariable analysis for risk of LOHS > 8 days, the 2nd period, ERAS and ERAS + NutriCatt groups showed a protective effect. These results were confirmed for both minor and major resections. LOHS was significantly lower in ERAS + Nutricatt group than in ERAS group, without increasing risk of postoperative complications, although the rate of laparoscopic resections was similar in these two groups and complexity of liver resections was significantly higher in the last period. Conclusions: Adoption of a personalized nutritional protocol with BCAA supplementation within the ERAS program for liver resections was a safe and effective approach that may impact on reducing the LOHS.

Published
2020

8. Laparoscopic Liver Resection of Segment 7 for Hepatocellular Carcinoma with an Ultrasound-Guided Trans-Parenchymal Approach to Segmental Pedicle

Author

Giuliante, Felice, Ardito, Francesco, Vellone, Maria, Mele, Caterina, Panettieri, Elena, Bellobono, M., De Rose, A. M., Giuliante F. (ORCID:0000-0001-9517-8220), Ardito F. (ORCID:0000-0003-1596-2862), Vellone M. (ORCID:0000-0002-7628-4092), Mele C., Panettieri E., Giuliante, Felice, Ardito, Francesco, Vellone, Maria, Mele, Caterina, Panettieri, Elena, Bellobono, M., De Rose, A. M., Giuliante F. (ORCID:0000-0001-9517-8220), Ardito F. (ORCID:0000-0003-1596-2862), Vellone M. (ORCID:0000-0002-7628-4092), Mele C., and Panettieri E.

Abstract

No abstract available

Published
2020

9. The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases

Author

Basso, M., Corallo, S., Calegari, M. A., Zurlo, I. V., Ardito, F., Vellone, M., Marchesani, S., Orlandi, A., Dadduzio, V., Fuca, G., Di Dio, C., Mele, C., Barbaro, B., Strippoli, A., Coppola, A., Cassano, A., Bria, E., Barone, C. A., Giuliante, F., Basso M., Calegari M. A., Zurlo I. V., Ardito F. (ORCID:0000-0003-1596-2862), Vellone M. (ORCID:0000-0002-7628-4092), Orlandi A. (ORCID:0000-0001-5253-4678), Dadduzio V., Mele C., Barbaro B. (ORCID:0000-0002-9638-543X), Strippoli A., Cassano A. (ORCID:0000-0002-3311-7163), Bria E. (ORCID:0000-0002-2333-704X), Barone C. A., Giuliante F. (ORCID:0000-0001-9517-8220), Basso, M., Corallo, S., Calegari, M. A., Zurlo, I. V., Ardito, F., Vellone, M., Marchesani, S., Orlandi, A., Dadduzio, V., Fuca, G., Di Dio, C., Mele, C., Barbaro, B., Strippoli, A., Coppola, A., Cassano, A., Bria, E., Barone, C. A., Giuliante, F., Basso M., Calegari M. A., Zurlo I. V., Ardito F. (ORCID:0000-0003-1596-2862), Vellone M. (ORCID:0000-0002-7628-4092), Orlandi A. (ORCID:0000-0001-5253-4678), Dadduzio V., Mele C., Barbaro B. (ORCID:0000-0002-9638-543X), Strippoli A., Cassano A. (ORCID:0000-0002-3311-7163), Bria E. (ORCID:0000-0002-2333-704X), Barone C. A., and Giuliante F. (ORCID:0000-0001-9517-8220)

Abstract

Hepatic resection is the gold standard treatment for patients affected by liver-limited colorectal metastases. Reports addressing the impact of multidisciplinary team (MDT) evaluation on survival are controversial. The aim of this study was to evaluate the benefit of MDT management in these patients in our Institution experience. The objective of the analysis was to compare survivals of patients managed within our MDT (MDT cohort) to those of patients referred to surgery from other hospitals without MDT discussion (non-MDT cohort). Of the 523 patients, 229 were included in the MDT cohort and 294 in the non-MDT cohort. No difference between the two groups was found in terms of median overall survival (52.5 vs 53.6 months; HR 1.13; 95% CI, 0.88–1.45; p = 0.344). In the MDT cohort there was a higher number of metastases (4.5 vs 2.7; p < 0.0001). The median duration of chemotherapy was lower in MDT patients (8 vs 10 cycles; p < 0.001). Post-operative morbidity was lower in the MDT cohort (6.2 vs 21.5%; p < 0.001). One hundred and ninety-seven patients in each group were matched by propensity score and no significant difference was observed between the two groups in terms of OS and DFS. Our study does not demonstrate a survival benefit from MDT management, but it allows surgery to patients with a more advanced disease. MDT assessment reduces the median duration of chemotherapy and post-operative morbidities.

Published
2020

10. Personalized Therapy in a Multidisciplinary Team Improves Survival in Patient with HCC: The Hepatocatt Experience

Author

Rinninella, Emanuele, Ponziani, Francesca Romana, Biolato, Marco, Siciliano, M, D'Aversa, F, Laterza, L, Ianiro, Gianluca, Montagna, M, Tortora, Annalisa, Cesario, Valentina, Campanale, Mariachiara, De Matthaeis, Nicoletta, Miele, Luca, Riccardi, Laura, Zocco, Maria Assunta, Saviano, Angela, Abbate, Valeria, Avolio, Alfonso Wolfango, Vellone, Maria, Basso, M, Iezzi, Roberto, De Gaetano, Anna Maria, Bonomo, Lorenzo, Agnes, Salvatore, Giuliante, Felice, Vecchio, Fabio Maria, Barone, C, Rapaccini, Gian Ludovico, Pompili, Maurizio, Grieco, A, Gasbarrini, Antonio, Rinninella, E (ORCID:0000-0002-9165-2367), Ponziani, FR (ORCID:0000-0002-5924-6238), Biolato, M, Ianiro, G (ORCID:0000-0002-8318-0515), Tortora, A, Cesario, V, Campanale, M, de Matthaeis, N, Miele, L (ORCID:0000-0003-3464-0068), Riccardi, L, Zocco, MA (ORCID:0000-0002-0814-9542), Saviano, A (ORCID:0000-0002-2820-7180), Abbate, V, Avolio, AW (ORCID:0000-0003-2491-7625), Vellone, M (ORCID:0000-0002-7628-4092), Iezzi, R (ORCID:0000-0002-2791-481X), De Gaetano, AM (ORCID:0000-0002-7493-9462), Bonomo, L (ORCID:0000-0001-5101-9367), Agnes, S (ORCID:0000-0002-3341-4221), Giuliante, F (ORCID:0000-0001-9517-8220), Vecchio, FM (ORCID:0000-0002-9197-2264), Rapaccini, GL (ORCID:0000-0002-6467-857X), Pompili, M (ORCID:0000-0001-6699-7980), Gasbarrini, A (ORCID:0000-0002-7278-4823), Rinninella, Emanuele, Ponziani, Francesca Romana, Biolato, Marco, Siciliano, M, D'Aversa, F, Laterza, L, Ianiro, Gianluca, Montagna, M, Tortora, Annalisa, Cesario, Valentina, Campanale, Mariachiara, De Matthaeis, Nicoletta, Miele, Luca, Riccardi, Laura, Zocco, Maria Assunta, Saviano, Angela, Abbate, Valeria, Avolio, Alfonso Wolfango, Vellone, Maria, Basso, M, Iezzi, Roberto, De Gaetano, Anna Maria, Bonomo, Lorenzo, Agnes, Salvatore, Giuliante, Felice, Vecchio, Fabio Maria, Barone, C, Rapaccini, Gian Ludovico, Pompili, Maurizio, Grieco, A, Gasbarrini, Antonio, Rinninella, E (ORCID:0000-0002-9165-2367), Ponziani, FR (ORCID:0000-0002-5924-6238), Biolato, M, Ianiro, G (ORCID:0000-0002-8318-0515), Tortora, A, Cesario, V, Campanale, M, de Matthaeis, N, Miele, L (ORCID:0000-0003-3464-0068), Riccardi, L, Zocco, MA (ORCID:0000-0002-0814-9542), Saviano, A (ORCID:0000-0002-2820-7180), Abbate, V, Avolio, AW (ORCID:0000-0003-2491-7625), Vellone, M (ORCID:0000-0002-7628-4092), Iezzi, R (ORCID:0000-0002-2791-481X), De Gaetano, AM (ORCID:0000-0002-7493-9462), Bonomo, L (ORCID:0000-0001-5101-9367), Agnes, S (ORCID:0000-0002-3341-4221), Giuliante, F (ORCID:0000-0001-9517-8220), Vecchio, FM (ORCID:0000-0002-9197-2264), Rapaccini, GL (ORCID:0000-0002-6467-857X), Pompili, M (ORCID:0000-0001-6699-7980), and Gasbarrini, A (ORCID:0000-0002-7278-4823)

Abstract

N/A

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results